TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06748872: EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma An

Sponsor: Medigene AG · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 55 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06748872 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06748872 Rescue Dossier →